In addition, previous studies have investigated the role of ATR inhibition as a means of increasing the tumor mutational burden and the production of neoantigens, which may improve the sensitivity to immune checkpoint inhibitors due to elevated antigen presentation. The gene discussed is ATR; the disease is neoplasm.